Press Releases
-
Avenue Therapeutics Prices Initial Public Offering of $33,000,000 of Common Stock
June 26, 2017New York, NY, June 26, 2017 —- Avenue Therapeutics, Inc. (“Avenue”), a Fortress Biotech, Inc. (NASDAQ: FBIO) company, announced today the pricing of its initial public offering of 5,500,000 shares of common stock at an initial public offering price of $6.00 per share. The gross proceeds to Avenue from the initial public offering are expected to be $33,000,000, before underwriting discounts and commissions and other estimated offering expenses. Avenue has granted the underwriters a 30-day option to purchase up to 825,000 additional shares of common stock, which may be purchased solely for the purpose of covering over-allotments, if any, at the public offering price less the underwriting discounts and commissions.
-
Avenue Therapeutics Receives Notice of Allowance for a New Patent Application Covering Methods of Administration for Intravenous Tramadol
May 19, 2017New York, NY – May 19, 2017 – Avenue Therapeutics, Inc. (“Avenue”), a Fortress Biotech (NASDAQ: FBIO) Company, today announced that Notice of Allowance has now been received from the U.S. Patent and Trademark Office (USPTO) for a new patent application (U.S. Application No. 15/163,111), entitled “Intravenous Administration of Tramadol.” The patent application describes and claims a dosing regimen of intravenous (IV) 50 mg tramadol that provides certain pharmacokinetic parameters that are similar to those of 100 mg tramadol HCl administered orally every 6 hours at steady state.
-
Avenue Therapeutics Receives Notices of Allowance for Patent Applications Covering Methods of Administration for Intravenous Tramadol
January 3, 2017New York, NY – January 3, 2017 – Avenue Therapeutics, Inc. (“Avenue”), a Fortress Biotech (NASDAQ: FBIO) Company, today announced that Notices of Allowance have now been received from the U.S. Patent and Trademark Office (USPTO) for two patent applications that cover methods of administration for its lead product candidate intravenous (IV) tramadol.
-
Avenue Therapeutics Files to Become a Public Reporting Company
December 30, 2015New York, NY – December 30, 2015 – Avenue Therapeutics, Inc. (“Avenue”), a Fortress Biotech, Inc.
(NASDAQ: FBIO) Company, announced that it filed a registration statement on Form 10 with the Securities
and Exchange Commission (“SEC”) under the Securities Exchange Act of 1934, as amended, for the
purpose of becoming a reporting company.
Click to Download PDF -
CORONADO BIOSCIENCES IN-LICENSES IV TRAMADOL, A PHASE III READY ASSET, FROM REVOGENEX IRELAND LTD.
February 18, 2015Forms Subsidiary to Build Portfolio of Acute Care Products Including IV Tramadol
New York, NY – February 18, 2015– Coronado Biosciences, Inc. (NASDAQ: CNDO) has obtained an exclusive license to an intravenous (IV) formulation of tramadol for the U.S. market from Revogenex Ireland Ltd, a privately held company in Dublin, Ireland. Coronado has formed a wholly owned subsidiary, Avenue Therapeutics, Inc., to acquire, in-license, develop and commercialize products principally for use in the U.S. hospital market. Coronado will transfer the Revogenex license to Avenue Therapeutics, Inc. In addition to IV tramadol, Avenue Therapeutics plans to seek additional products.
Click to Read More
